Skip to main navigation
MoonLake MoonLake
e: info@moonlaketx.com
  • About us
    • About MoonLake TX
    • Careers
    • Team
  • Science
    • The science
    • Therapeutic focus
    • Pipeline
  • Investor relations
    • Investors overview
    • Stock information
    • Press releases
    • Events & presentations
    • Corporate governance
    • Financials & filings
    • Email alerts
Site - Main
  • About us
    • About MoonLake TX
    • Careers
    • Team
  • Science
    • The science
    • Therapeutic focus
    • Pipeline
  • Investor relations
    • Investors overview
    • Stock information
    • Press releases
    • Events & presentations
    • Corporate governance
    • Financials & filings
    • Email alerts
e: info@moonlaketx.com

INVESTOR RELATIONS

Press Releases

  • All News
  • 2022
  • 2021
May 12 2022
MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
Read More +
May 9 2022
MoonLake Immunotherapeutics announces the publication of new long-term disease control data from a Phase 2b Psoriasis trial of the Nanobody® sonelokimab
Read More +
Apr 5 2022
MoonLake Immunotherapeutics AG Announces Closing of Business Combination with Helix Acquisition Corp.
Read More +
Mar 24 2022
MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa with HiSCR75 as the primary endpoint
Read More +
Oct 4 2021
MoonLake Immunotherapeutics AG and Helix Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing Tri-specific Nanobody® Sonelokimab
Read More +
Aug 10 2021
MoonLake Immunotherapeutics appoints former Kymab CEO Simon Sturge as Chairman and Spike Loy to the Board of Directors
Read More +
Jul 1 2021
MoonLake Immunotherapeutics appoints Jorge Santos da Silva as CEO and Matthias Bodenstedt as CFO
Read More +
May 6 2021
MoonLake Immunotherapeutics announces publication in The Lancet
Read More +
May 3 2021
MoonLake In-licensing and launch
Read More +
Site - Investor Tools
Print Page
RSS Feeds
Email Alerts
Contact IR

Contact Us

MoonLake Immunotherapeutics AG Dorfstrasse 29, 6300 Zug, Schweiz/Switzerland
e: info@moonlaketx.com
media: media@moonlaketx.com
IR: ir@moonlaketx.com
LinkedIn

Quick Links

  • Home
  • About us
  • Team
  • Science
  • Pipeline
  • Therapeutic focus
  • Investor relations
  • Careers
  • Privacy policy

© 2022 -  MoonLake Immunotherapeutics

Privacy Policy